Alveolar sphingolipids generated in response to TNF-alpha modifies surfactant biophysical activity.
Sphingolipids represent a diverse group of bioactive lipid species that are generated intracellularly in response to tumor necrosis factor-alpha (TNF-alpha) and are implicated as potential mediators of acute lung injury. The purpose of these studies was to determine whether there was an extracellular, TNF-alpha-regulated pool of sphingolipids in the alveolus that modulates the surface tension lowering capacity of pulmonary surfactant. Intratracheal instillation of TNF-alpha in adult rats led to a twofold increase in the amount of surfactant-associated ceramide and tended to decrease levels of sphingomyelin without significantly altering sphingosine or sphinganine content. TNF-alpha induction of alveolar ceramide was associated with nearly an 80% increase in acid sphingomyelinase activity recovered in cell-free alveolar lavage. Ceramide administered in a dose-dependent manner potently antagonized the surface tension lowering effects of natural surfactant in vitro. Intratracheal TNF-alpha and ceramide treatment of rats significantly increased lung permeability, as was evidenced by extravasation of Evans blue dye into alveolar lavage and lung tissue. Thus these studies are the first to demonstrate the existence of a cytokine-regulated alveolar pool of sphingomyelin hydrolysis products that impairs the biophysical properties of the alveolar surfactant film. The results also suggest the presence of a secretory alveolar sphingomylinase that is TNF-alpha responsive and mediates effects of the cytokine on alveolar sphingolipid metabolism.
Ryan
Alan J
AJ
Department of Internal Medicine, The University of Iowa College of Medicine, Iowa City 52242, USA.
McCoy
Diann M
DM
McGowan
Stephen E
SE
Salome
Ronald G
RG
Mallampalli
Rama K
RK
D000818:Animals; D055592:Biophysical Phenomena; D001703:Biophysics; D002199:Capillary Permeability / Q000187:drug effects; D002518:Ceramides / Q000494:pharmacology; D004396:Coloring Agents / Q000493:pharmacokinetics; D005070:Evans Blue / Q000493:pharmacokinetics; D008297:Male; D011650:Pulmonary Alveoli / Q000378:metabolism*; D011652:Pulmonary Circulation / Q000187:drug effects; D011663:Pulmonary Surfactants / Q000378:metabolism*; D051381:Rats; D017207:Rats, Sprague-Dawley; D013107:Sphingolipids / Q000502:physiology*; D013108:Sphingomyelin Phosphodiesterase / Q000378:metabolism; D013500:Surface Tension; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology*
D002518:Ceramides; D004396:Coloring Agents; D011663:Pulmonary Surfactants; D013107:Sphingolipids; D014409:Tumor Necrosis Factor-alpha; D005070:Evans Blue; D013108:Sphingomyelin Phosphodiesterase